Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 21Gastrointestinal 18Genitourinary 12Gynecologic 11CNS 8Other hematologic neoplasm 7Other solid neoplasm 4Lymphoid 4Head & Neck 3Sarcoma 2Dermatologic 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Other neoplasm 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Multiple Myeloma 1Lymphoproliferative Disorders 1

Interventions

Dexamethasone 881Bortezomib 478Lenalidomide 467Cyclophosphamide 367Melphalan 275Calcium Dobesilate 264daratumumab 240pomalidomide 215carfilzomib 188fludarabine phosphate 141fludarabine 137Thalidomide 125Peripheral Blood Stem Cell Transplantation 120Filgrastim 115ixazomib 94Mycophenolic Acid 91Granulocyte Colony-Stimulating Factor 90Busulfan 89Whole-Body Irradiation 88dexamethasone acetate 87Tacrolimus 79dexamethasone 21-phosphate 74isatuximab 68Cyclosporine 68auricularum 67Prednisone 67elotuzumab 63belantamab mafodotin 59Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Testing × Plasma cell × Clear all
NCT06630104 2026-01-08

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

Mayo Clinic

Phase NA Recruiting
82 enrolled
LymphoidPlasma cell

Lymphoproliferative Disorders, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡